Table 1.
Baseline characteristics of the study group with IgAN.
Fig 1.
Correlation of circulating TNFRs with eGFR (A) and uPCR (B) at the time of kidney biopsy Log-transformed circulating TNFR1 and TNFR2 were correlated negatively with eGFR (A) and positively with uPCR (B), respectively.
eGFR, estimated glomerular filtration rate; TNFR, tumor necrosis factor receptors; uPCR, urine protein-creatinine ratio.
Table 2.
Clinical parameters according to TNFR1 and TNFR2 concentrations at the time of kidney biopsy.
Table 3.
Spearman correlation coefficients between various clinical parameters in IgAN patients.
Fig 2.
Associations between the concentrations of TNFRs and renal histologic findings.
The severity of glomerular sclerosis and interstitial fibrosis/tubular atrophy significantly increased as the concentrations of TNFR1 and TNFR2 increased in both groups with eGFR ≥ 60 mL/min/1.73 m2 (A) and with eGFR < 60 mL/min/1.73 m2 (B). TNFR, tumor necrosis factor receptors.
Fig 3.
The risk for renal progression according to circulating TNFRs.
The highest quartile of TNFR1 and TNFR2 were significantly associated with higher risk for renal progression compared to those in other quartiles of TNFRs, regardless of renal function at the time of diagnosis. (A) Total study population, (B) Patients with eGFR ≥ 60 ml/min/1.73 m2, (C) Patients with eGFR < 60 ml/min/1.73 m2. eGFR, estimated glomerular filtration rate; TNFR, tumor necrosis factor receptors.
Table 4.
Risk factors for renal progression in multivariate Cox regression analysis.
Fig 4.
ROC curve analysis with various biomarkers for renal progression.
The concentrations of circulating TNFRs can best discriminate patients with renal progression than eGFR or uPCR. eGFR, estimated glomerular filtration rate; TNFR, tumor necrosis factor receptors; UPCR, urine protein creatinine ratio.